AbbVie

=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-08-14 10b5-1 Pre-arranged Plan: No --- Issuer --- Name: AbbVie Inc. (ABBV) CIK: 0001551152 --- Reporting Owner --- Name: Donoghoe Nicholas CIK: 0001762951 Role: Officer (EVP, CHIEF BUS/STRAT OFFICER) --- Non-Derivative Transactions --- [Transaction #1] Security: Common Stock, $0.01 par value Date: 2026-08-14 | Code: M (Exercise of derivative) Shares: +32,710 | Price: $79.02 Total Value: $2,584,744.20 Shares Owned After: 107,140 | Ownership: D (Direct) [Transaction #2] Security: Common Stock, $0.01 par value Date: 2026-08-14 | Code: S (Open market sale) Shares: -32,710 | Price: $250.00 Total Value: $8,177,500.00 Shares Owned After: 74,430 | Ownership: D (Direct) --- Derivative Transactions --- [Transaction #1] Security: Option (Right to buy) Date: 2026-08-14 | Code: M (Exercise of derivative) Shares: -32,710 | Price: $0.00 Exercisable: N/A | Expires: 2029-02-20 Shares Owned After: 0 | Ownership: D (Direct) Footnotes: [F1] Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 10,904 on February 21, 2020, 10,903 on February 21, 2021, and 10,903 on February 21, 2022. --- Footnotes (Complete Index) --- F1: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 10,904 on February 21, 2020, 10,903 on February 21, 2021, and 10,903 on February 21, 2022. --- Signature --- /s/ /s/ T.O. Odutayo, Attorney-in-Fact for Nicholas J. Donoghoe (2026-08-18)